Caplin Point Laboratories Limited — Updates, 14-05-2025: Press Release

Caplin Point’s subsidiary, Caplin Steriles, received final USFDA approval for its generic Haloperidol Decanoate Injection, targeting a $16.4 million US market. With 38 ANDA approvals and 40+ filings planned, Caplin Steriles is expanding its injectable and ophthalmic portfolio. This approval bolsters Caplin Point’s presence in regulated markets, reinforcing its growth focus on sterile injectables and emerging markets.